The Interstitial Lung Fibrosis drugs in development market research report provides comprehensive information on the therapeutics under development for Interstitial Lung Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Interstitial Lung Fibrosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Interstitial Lung Fibrosis and features dormant and discontinued products.
GlobalData tracks 343 drugs in development for Interstitial Lung Fibrosis by 281 companies/universities/institutes. The top development phase for Interstitial Lung Fibrosis is preclinical with 178 drugs in that stage. The Interstitial Lung Fibrosis pipeline has 327 drugs in development by companies and 16 by universities/ institutes. Some of the companies in the Interstitial Lung Fibrosis pipeline products market are: AstraZeneca, Createrna Science and Technology and MD Healthcare.
The key targets in the Interstitial Lung Fibrosis pipeline products market include Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1), Lysophosphatidic Acid Receptor 1 (Lysophosphatidic Acid Receptor Edg 2 or LPAR1), and Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 2 (Autotaxin or Extracellular Lysophospholipase D or ENPP2 or EC 3.1.4.39).
The key mechanisms of action in the Interstitial Lung Fibrosis pipeline product include Rho Associated Protein Kinase 2 (Rho Kinase 2 or Rho Associated Coiled Coil Containing Protein Kinase 2 or p164 ROCK 2 or ROCK2 or EC 2.7.11.1) Inhibitor with eight drugs in Phase II. The Interstitial Lung Fibrosis pipeline products include 14 routes of administration with the top ROA being Oral and 19 key molecule types in the Interstitial Lung Fibrosis pipeline products market including Small Molecule, and Monoclonal Antibody.
Interstitial Lung Fibrosis overview
Interstitial Lung Fibrosis or interstitial lung disease (ILD) is a group of diseases that cause scarring of the lungs (fibrosis) or lung parenchyma. If untreated it can lead to respiratory failure and death. Symptoms start with inflammation and can result in bronchiolitis, vasculitis, and alveolitis. Exposure to hazardous chemicals or materials like asbestos, hypersensitivity, drug-induced, underlying autoimmune conditions, family history, smoking, and exposure to radiation are common factors while SOB, discomfort in the chest, loss of appetite, dry cough are common symptoms. Validated by chest x-ray, biopsy, bronchoscopy, PFT. Corticosteroids are prescribed to treat inflammation, oxygen therapy if breathlessness and other symptomatic management.
For a complete picture of Interstitial Lung Fibrosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
